Registry of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia
ALLTARGETOBS
Observatory for Patients Treated for Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia With Oncogenetic Features.
1 other identifier
observational
80
1 country
31
Brief Summary
In order to improve the outcome of relapsed and/or refractory T-cell precursor acute lymphoblastic leukemia (T-ALL) patients, and to facilitate the use of oncogenetic targeted therapies in these patients, we set up an observational cohort, collecting clinical and biological information's from patients with T-ALL in relapse or refractory, as well as the use or not of a targeted therapy. The analysis of the cohort will allow us to evaluate the impact of this therapeutic strategies on the patients' fate, and to facilitate access to innovation and personalized medicine for these patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2021
Typical duration for all trials
31 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 14, 2021
CompletedFirst Submitted
Initial submission to the registry
March 13, 2023
CompletedFirst Posted
Study publicly available on registry
April 27, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2024
CompletedApril 27, 2023
April 1, 2023
2 years
March 13, 2023
April 14, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Response rate defined as complete remission and remission without complete hematological recovery (CR + CRi).
Response rate defined as complete remission and remission without complete hematological recovery (CR + CRi).
3 months
Secondary Outcomes (8)
Performance Status of patients
3 months
Biological description of T-ALL
3 months
Description of the treatments received
3 months
Description of Overall response rate to treatment
2 years
Description of the relapse rate
2 years
- +3 more secondary outcomes
Eligibility Criteria
Patients 18 years of age or older, with relapsed or refractory T cell precursor-ALL or T-cell Lymphoblastic lymphoma, with oncogenetic analysis performed at diagnosis and/or relapse in the central laboratory.
You may qualify if:
- Patients 18 years of age or older
- Patients with relapsed or refractory T-cell precursor ALL or T-cell lymphoblastic lymphoma
- Oncogenetic analysis performed at diagnosis and/or relapse in the central laboratory
You may not qualify if:
- Patient who refuse to be registered
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (31)
CHU Amiens Picardie
Amiens, France
Chu Angers
Angers, France
CH Annecy Genevois
Annecy, France
Centre Hospitalier d'Argenteuil
Argenteuil, France
Centre Hospitalier Montfavet Avignon
Avignon, France
Centre Hospitalier de la Cote Basque
Bayonne, France
Hopital Avicenne
Bobigny, France
CHU de Bordeaux
Bordeaux, France
Centre Hospitalier Universitaire de CAEN
Caen, France
CHU Clermont Ferrand
Clermont-Ferrand, France
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, France
Hopital Henri Mondor
Créteil, France
CHU Dijon Bourgogne
Dijon, France
CHU Lille
Lille, France
Chu Limoges
Limoges, France
Hospices Civiles de Lyon
Lyon, France
Grand Hopital de l'Est Francilien
Meaux, France
CHU de Montpellier
Montpellier, France
Centre Hospitalier Emile Muller de Mulhouse
Mulhouse, France
CHU Nancy
Nancy, France
Centre anti-cancer Nice : Antoine Lacassagne
Nice, France
CHU de Nice
Nice, France
CHU Nîmes
Nîmes, France
Hopital Saint-Antoine
Paris, France
Hôpital Cochin
Paris, France
Centre Hospitalier de Perpignan
Perpignan, France
CHU de Rennes
Rennes, France
CHU Centre Hospitalier Universitaire de Saint-Étienne - Loire
Saint-Etienne, France
ONCOPOLE
Toulouse, France
Centre Hospitalier de Versailles
Versailles, France
Institut Gustave Roussy
Villejuif, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 2 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
March 13, 2023
First Posted
April 27, 2023
Study Start
December 14, 2021
Primary Completion
December 1, 2023
Study Completion
March 1, 2024
Last Updated
April 27, 2023
Record last verified: 2023-04